Search results
Results from the WOW.Com Content Network
IV dose 1-1.5mg/kg or 3 to 5 x ED 95. Paralysis occurs in one to two minutes. Clinical duration of action (time from drug administration to recovery of single twich to 25% of baseline) is 7-12 minutes. If IV access is unavailable, intramuscular administration 3-4mg/kg. Paralysis occurs at 4 minutes.
External inhibition is the observed decrease of the response of a conditioned reaction when an external (distracting) stimulus that was not part of the original conditioned response set is introduced.
[4] The term "anticholinergic" is typically used to refer to antimuscarinics which competitively inhibit the binding of ACh to muscarinic acetylcholine receptors; such agents do not antagonize the binding at nicotinic acetylcholine receptors at the neuromuscular junction, although the term is sometimes used to refer to agents which do so. [3] [5]
Untransformed human cells exhibit normal cellular behavior and mediate their growth and proliferation via interplay between environmental nutrients, growth factor signaling, and cell density. As cell density increases and the culture becomes confluent, they initiate cell cycle arrest and downregulate proliferation and mitogen signaling pathways ...
Some research is devoted to finding combinations of extant antibiotics which when combined exhibit synergy. A classic example of this effect is the interaction between β-lactams, which damage the bacteria cell membrane, and aminoglycosides, which inhibit protein synthesis. [1]
Releasing hormones and inhibiting hormones are hormones whose main purpose is to control the release of other hormones, either by stimulating or inhibiting their release. . They are also called liberins (/ ˈ l ɪ b ə r ɪ n z /) and statins (/ ˈ s t æ t ɪ n z /) (respectively), or releasing factors and inhibiting fac
Irreversible inhibitors covalently bind to an enzyme, and this type of inhibition can therefore not be readily reversed. [51] Irreversible inhibitors often contain reactive functional groups such as nitrogen mustards, aldehydes, haloalkanes, alkenes, Michael acceptors, phenyl sulfonates, or fluorophosphonates. [52]
Therefore, SMO has been a primary target in the development of Hedgehog pathway inhibitors. Two such inhibitors, Sonidegib and Vismodegib have been approved by the Food and Drug Administration (FDA) for treating basal cell carcinoma. Multiple other SMO inhibitors are in active clinical trials.